Department of Microbiology, Bristol-Myers Squibb Company, Wallingford, CT 06492, USA
Sir,
BMS-284756 is a novel des-fluoro(6) quinolone and is more active in vitro than marketed quinolones against staphylococci, Streptococcus pneumoniae and other ciprofloxacin-resistant Gram-positive cocci.1,2 The rapid development of resistance to ciprofloxacin among methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) strains has led to doubts about quinolone use against this organism.3 The fact that clinical resistance developed quickly with ciprofloxacin is not surprising (ciprofloxacin susceptibility breakpoint = 1 mg/L), given its relatively borderline activity against staphylococci (MIC50 0.5 mg/L for MRSA).1 BMS-284756 is 10-fold more active than ciprofloxacin against staphylococci (MIC50 0.03 mg/L)1 and has three-fold greater drug exposure (3 x AUC of ciprofloxacin using standard doses),4 indicating that BMS-284756 may be of potential use for treatment of MRSA infection.
In this study, we compared the activity of BMS-284756 with those of levofloxacin and ciprofloxacin against 144 mecA+ and 124 mecA- staphylococcal strains. All strains were clinical isolates collected within the past 5 years. GISA (glycopeptide-intermediate susceptible S. aureus) strains were kindly provided by T. Walsh (Bristol, UK), and the BORSA (borderline oxacillin-resistant S. aureus) isolates were obtained from J. Swenson (CDC, Atlanta, GA, USA) and L. Jette (Labortoire de Sante Publique de Quebec, Canada). S. aureus was identified by a positive tube coagulase test. Coagulase-negative staphylococcal strains were speciated using the API-Staph system (bioMérieux, Hazelwood, MO, USA).
BMS-284756 was obtained from Toyama Chemical Co. Ltd, Toyama, Japan; ciprofloxacin from Bayer Corporation, West Haven, CT, USA; levofloxacin was extracted and purified from commercially available tablets and determined to be >95% pure by high-performance liquid chromatography; and oxacillin was purchased from Sigma Chemical Co., St Louis, MO, USA.
Genotypic determination of methicillin resistance was done by detection of the mecA gene, following the PCR procedure of Bignardi et al.5 MICs were determined by an agar dilution method, using MuellerHinton agar (MHA), and, for oxacillin, MHA + 2% NaCl. Bacterial inoculum size was c. 5 x 104 cfu/spot, and plates were incubated at 35°C for 24 h. The MIC endpoint was read as the lowest drug concentration that prevented visible growth.
BMS-284756 was the most active quinolone against staphylococci. Based on MIC90 or modal MIC values (Table), BMS-284756 was more active than ciprofloxacin and levofloxacin, by four to eight times against mecA- staphylococcal strains, with an even greater differential (32128 times) against BORSA strains.
|
Based on its AUC following a 400 mg oral dose, the tentative BMS-284756 susceptibility breakpoint for MRSA strains is 2 mg/L.4 Ninety per cent of MRSA, 56% of GISA, 97% of oxacillin-resistant S. epidermidis, 89% of mecA+ S. haemolyticus and 100% of all mecA+ strains belonging to other coagulase-negative Staphylococcus spp. had BMS-284756 MICs of
2 mg/L.
These results indicate that BMS-284756 is more active than comparator quinolones against methicillin-resistant staphylococci. Given that these strains are often multidrug resistant, and that the few agents with activity against MRSA (such as vancomycin, linezolid and quinupristin/ dalfopristin) are bacteriostatic or poorly bactericidal,6 BMS-284756 may provide a therapeutic alternative for infections caused by these pathogens.
Notes
* Corresponding author. Tel: +1-203-677-6370; Fax: +1-203-677-6771; E-mail: fungtomj{at}bms.com
References
1
.
Fung-Tomc, J. C., Minassian, B., Kolek, B., Huczko, E., Aleksunes, L., Stickle, T. et al. (2000). Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrobial Agents and Chemotherapy 44, 33516.
2 . Jones, R. N., Pfaller, M. A., Stilwell, M. & the SENTRY Antimicrobial Surveillance Program Participants Group. (2001). Activity and spectrum of BMS-284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. Diagnostic Microbiology and Infectious Disease 39, 1335.[ISI][Medline]
3 . Issacs, R. D., Kunke, P. J., Cohen, R. L. & Smith, J. W. (1988). Ciprofloxacin resistance in epidemic methicillin-resistant Staphyhlococcus aureus. Lancet ii, 843.
4 . Gajjar, D. A., Grasela, D. M., Bello, A., Ge, Z. & Christopher, L. (2000). Safety, tolerability, and pharmacokinetics of BMS-284756, a novel des-F(6)-quinolone, following single oral doses in healthy adult subjects. In Program and Abstracts of the Forthieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract 2259, p. 36. American Society for Microbiology, Washington, DC.
5 . Bignardi, G. E., Woodford, N., Chapman, A., Johnson, A. P. & Speller, D. C. E. (1996). Detection of the mec-A gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillin resistance. Journal of Antimicrobial Chemotherapy 37, 5363.[Abstract]
6
.
Rybak, M. J., Hershberger, E., Moldovan, T. & Grucz, R. G. (2000). In vitro activities of daptomycin, vancomycin, linezolid, and quinupristindalfopristin, against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrobial Agents and Chemotherapy 44, 10626.